HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

Prazosin Hydrochloride

HCID 68546
NotesReactions

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
19237-84-4
Standard SMILES
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl
InChIKey
WFXFYZULCQKPIP-UHFFFAOYSA-N
Molecular formula
C19H22ClN5O4
Average molar mass
419.9 g/mol
Monoisotopic mass
419.13603186

Overview

Prazosin Hydrochloride is a synthetic piperazine derivative with hypotensive antiadrenergic properties, Prazosin Hydrochloride reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention. (NCI04)

Names & identifiers

Preferred name
Prazosin Hydrochloride
IUPAC
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;hydrochloride
English name
Prazosin hydrochloride
Molecular formula
C19H22ClN5O4
Molecular weight
419.86

Names & synonyms

Prazosin hydrochloride19237-84-4Prazosin HClPeripressMinipress XlHypovaseSinetens1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochlorideCP-12299-1Prazosin clorhidratoCP-12,299-11-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride
Show more names
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone hydrochloridepratsiolVasoflexAdversuten
X0Z7454B902-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloridePiperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochlorideDTXSID50172822NSC2928102-[4-(2-Furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline hydrochlorideAlpress LPCHEBI:8365

Database identifiers

CAS
19237-84-4
PubChem CID
68546
DTXSID

Properties

Computed structural propertiesFilling in

Topological polar surface area
107 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
8
Rotatable bonds
4
Heavy atoms
29
Formal charge
0
Complexity
544

Experimental & physicochemical properties

Color/FormWhite to tan powder
Solubility · 3 items

Soluble at ambient temperatures (mg/ml): acetone, 0.0072; methanol, 6.4; ethanol, 0.84; dimethylformamide, 1.3; dimethylacetamide, 1.2; chloroform, 0.041

In water, 1.4 mg/ml @ pH approx 3.5

61.9 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting PointCrystals. MP: 278-280 °C /Prazosin/
Stability/Shelf LifePrazosin hydrochloride capsules should be stored in well closed, light resistant containers at 15-30 °C.
Collision Cross Section193.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
277 · 277 - 280 °C
storage temp.
2 · 2-8°C

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (56.6%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 76 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationPrazosin hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride: Environment tier I assessment
FDA Requirements · 2 items

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl prazosin hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Special Reports · 1 item

Khoury AF, Kaplan NM; Alpha-blocker Therapy of Hypertension. An Unfulfilled Promise. JAMA 266 (3): 394-8 (1991). For various reasons, the alpha 1-receptor blocker prazosin has been used infrequently as initial therapy for hypertension. A summary of the published data on efficacy, side effects, and special properties of alpha 1-receptor blockers indicates that they will probably be used more extensively, particularly because of their ability to improve lipid and glucose-insulin metabolism.

Chemistry & industry

Pharmacology

Mechanism of Action · 3 items

Animal studies indicate that prazosin does not have its antihypertensive effect in the CNS. Prazosin does not interfere with nerve impulse transmission across sympathetic ganglia nor does it cause adrenergic neuronal blockade.

The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Animal studies have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha- blockers, the antihypertensive action of prazosin is usually not accompanied by reflex tachycardia.

Prazosin ... is a very potent and selective alpha 1-adrenergic antagonist. ... Interestingly, the drug also is a relatively potent inhibitor of cyclic nucleotide phosphodiesterases...

Biological Half-Life · 2 items

Elimination half-life approx 3 hr.

The plasma half-life of prazosin after oral administration has been reported to be 2-4 hr.

Metabolism/Metabolites · 2 items

Animal studies show that prazosin hydrochloride is metabolized extensively in the liver, principally by demethylation and conjugation, and excreted as unchanged drug (5-11%) and metabolites. Four of the metabolites have been shown to possess 10-25% of the hypotensive activity of prazosin and they may contribute to the antihypertensive effect of the drug.

The 6-O-demethyl and 7-O-demethyl analogues of the new antihypertensive drug prazosin [2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline hydrochloride] have been unequivocally synthesized via separate 10-step reaction sequences starting from isovanillin and vanillin, respectively. The 6-O-demethyl derivative was found to be identical with the major prazosin metabolite formed in dog and rat, while the 7-O-demethyl derivative was identical with another, less prevalent but significant metabolite. Two minor metabolites of prazosin, 2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline and 2,4-diamino-6,7-dimethoxyquinazoline, are also described. All 4 metabolites are less potent blood pressure lowering agents in dogs than prazosin but may contribute to its antihypertensive effect, since they account for a major portion of the administered dose.

Related reactions

4 records
New reaction record
HRID 372679 reaction equation
HRID 372679As productuspto-grants-1978_05
HRID 372680 reaction equation
HRID 372680As reactantuspto-grants-1978_05
HRID 840093 reaction equation
HRID 840093As reactantuspto-grants-2002_04
HRID 1680075 reaction equation
HRID 1680075As productuspto-grants-1981_06

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID50172822
ChEMBL
CHEMBL1558
UNII
X0Z7454B90
EC Number
242-903-4
solubility
2 O: · H2O: 1 mg/mL, clear, colorless
form
solid
color
white
Water Solubility
Soluble in dimethyl sulfoxide, ethanol, water, methanol.
Merck
14 · 14,7717
BRN
4303561 · 4303561
InChI
InChI=1S/C19H21N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22);1H
InChIKey
WFXFYZULCQKPIP-UHFFFAOYSA-N
SMILES
N1(C2=NC(N)=C3C(=N2)C=C(OC)C(OC)=C3)CCN(C(C2=CC=CO2)=O)CC1.[H]Cl
CAS DataBase Reference
19237 · 19237-84-4(CAS DataBase Reference)
FDA UNII
0 Z7454B90 · X0Z7454B90
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07,GHS08
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335-H361
Precautionary statements
201 · P201-P301+P312+P330-P302+P352-P305+P351+P338-P308+P313
target organs
Central nervous system
PPE
95 · dust mask type N95 (US), Eyeshields, Gloves
Hazard Codes
Xn
Risk Statements
22 · 22-36/37/38-62
Safety Statements
28 · 28-36
RIDADR
3249 · 3249
WGK Germany
3 · 3
RTECS
1350000 · VA1350000
F
10 · 10
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2934990002 · 2934990002
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 STOT · Repr. 2STOT RE 2STOT SE 3
Hazardous Substances Data
19237 · 19237-84-4(Hazardous Substances Data)
Toxicity
50 · dog,LD50,oral,> 700mg/kg (700mg/kg),GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDSKIDNEY, URETER, AND BLADDER: OTHER CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING,Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
Hazard Classes and CategoriesAcute Tox. 4 (56.6%)

Safety & protection

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxicology

Interactions · 2 items

When prazosin is administered with diuretics or other hypotensive agents, particularly beta-adrenergic blocking agents (eg, propranolol), the hypotensive effect of prazosin may be increased.

... prazosin hydrochloride has been administered without any adverse drug interaction in limited clinical experience to date with the following: cardiac glycosides -- digitalis and digoxin; hypoglycemics -- insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; tranquilizers and sedatives -- chlordiazepoxide, diazepam, phenobarbital; antigout -- allopurinol, colchicine, and probenecid; antiarrhythmics -- procainamide, propranolol and quinidine; analgesics, antipyretics and anti-inflammatories -- propoxyphene, aspirin, indomethacin, and phenylbutazone.

Milk Concentrations/Prazosin hydrochloride/ has been shown to be excreted in small amounts in human milk.
Human Toxicity Excerpts · 2 items

/HUMAN EXPOSURE STUDIES/ In overdosage, hypotension and CNS depression ranging from lethargy to coma are reported. In addition, priapism may occur.

/CASE REPORTS/ Ingestion of at least 50 mg of prazosin by a 2 yr old child produced profound drowsiness and depressed reflexes. There was no decrease in blood pressure and recovery was uneventful. A 19 yr old man who ingested approximately 200 mg of prazosin had normal CNS responses and slightly decreased blood pressure.

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Prazosin hydrochloride

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Acute Exposure/ ... Prazosin has been shown to exacerbate canine narcolepsy-cataplexy, probably secondary to inhibition of a subtype of alpha1-adrenergic receptor (eg, alpha1b) in the CNS.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ No carcinogenic potential was demonstrated in an 18 month study in rats with /prazosin hydrochloride/ ... at dose levels more than 225 times the usual maximum recommended human dose of 20 mg per day.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ /prazosin hydrochloride/ ... has been shown to be associated with decreased litter size at birth 1, 4, and 21 days of age in rats when given doses more than 225 times the usual maximum recommended human dose. No evidence of drug-related external, visceral, or skeletal fetal abnormalities were observed. No drug-related external, visceral, or skeletal abnormalities were observed in fetuses of pregnant rabbits and pregnant monkeys at doses more than 225 times and 12 times the usual maximum recommended human dose respectively.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Decreased fertility has occurred in male and female rats receiving prazosin dosages of 75 mg/kg but did not occur in those receiving 25 mg/kg. Testicular changes consisting of atrophy and necrosis have occurred in rats and dogs receiving prazosin dosages of 25 mg/kg daily for a year or longer but no such changes occurred in those receiving 10 mg/kg daily.

For more Non-Human Toxicity Excerpts (Complete) data for PRAZOSIN HYDROCHLORIDE (6 total), please visit the HSDB record page.

Antidote and Emergency Treatment · 2 items

Treatment with supportive care including intravenous fluid boluses and vasopressors such as dopamine were effective in the few overdose cases reported.

Maintain an open airway and assist ventilation if necessary.Hypotension usually respondes to supine positioning and iv crystalloid fluids. Occasionally pressor therapy is needed. there is no specific antidote. Administer activated charcoal.

Regulatory information

FDA Requirements · 2 items

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl prazosin hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Safety data

F
10
PPE
dust mask type N95 (US), Eyeshields, Gloves
wgk
3
rtecs
VA1350000
ridadr
3249
hs_code
2934990002
Toxicity
dog,LD50,oral,> 700mg/kg (700mg/kg),GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDSKIDNEY, URETER, AND BLADDER: OTHER CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING,Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
risk_code
22-36/37/38-62
Signal word
Warning
Symbol(GHS)
GHS07,GHS08
hazard_code
Xn
safety_code
28-36
hazard_class
6.1(b)
Storage Class
11 - Combustible Solids
packing_group
III
target organs
Central nervous system
Hazard statements
H302-H315-H319-H335-H361
Hazard Classifications
Repr. 2STOT RE 2STOT SE 3
Precautionary statements
P201-P301+P312+P330-P302+P352-P305+P351+P338-P308+P313
Hazardous Substances Data
19237-84-4(Hazardous Substances Data)
FDA Pharmacological Classification · 4 items

PRAZOSIN HCL

alpha-Adrenergic Blocker [EPC]; Adrenergic alpha-Antagonists [MoA]

PRAZOSIN HYDROCHLORIDE

Adrenergic alpha-Antagonists [MoA]; alpha-Adrenergic Blocker [EPC]

MeSH Pharmacological Classification · 2 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Absorption, Distribution and Excretion · 5 items

There is intraindividual and interindividual variation in the rate of absorption and plasma concentrations of prazosin. The absolute oral bioavailability of prazosin is also variable but is reported to average about 60% (range: 43-82%). Results of one study indicate that the presence of food may delay absorption of the drug in some patients, but does not affect the extent of absorption.

Following oral administration of prazosin hydrochloride, plasma concentrations of the drug reach a peak in 2-3 hrs in most fasting patients. Plasma concentrations of prazosin generally do not correlate with therapeutic effect. One manufacturer reports that plasma concentrations of the drug after a single 5 mg dose range from 0.01-0.075 ug/ml. Blood pressure begins to decrease within 2 hr after an oral dose; the maximum decrease occurs in 2-4 hr. The hypotensive effect of prazosin lasts less than 24 hr.

Animal studies indicate that prazosin is widely distributed in body tissues. After iv administration in dogs, highest concentrations of the drug are found in the lungs, coronary arteries, aorta, paw arteries and heart; the lowest concentrations are in the brain. During prazosin therapy, approximately 97% of the drug in plasma is bound to proteins. It is not known whether the drug crosses the placenta. Prazosin is distributed into milk in small amounts.

Approximately 6-10% of a dose is excreted in urine and the remainder in feces via bile.

The drug /prazosin hydrochloride/ is tightly bound to plasma proteins (primarily alpha1-acid glycoprotein), and only 5% of the drug is free in the circulation; diseases that modify the concentration of this protein (e.g., inflammatory processes) may change the free fraction. Prazosin is extensively metabolized in the liver, and little unchanged drug is excreted by the kidneys.

Uses & manufacturing

Uses · 2 items

MEDICATION

Use (kg; approx.) in Germany (2009): >10

Methods of ManufacturingPreparation: GB 1156973; Hess, US 3511836 (1969, 1970 both to Pfizer); Nl 7206067 (1972 to Brocades-Stheeman) ... . /Prazosin/
Formulations/Preparations · 5 items

Oral Capsules, 1 mg (of prazosin), Minipress, Pifizer; 2 mg (of prazosin), Minipress, Pifzer; 5 mg (of prazosin), Minipress, Pifizer.

Oral Capsules, 1 mg (of prazosin) with Polythiazide 0.5 mg, Minizide 1, Pifizer; 2 mg (of prazosin) with Polythiazide 0.5 mg, Minizide 2, Pfizer; 5 mg (of prazosin) with Polythiazide 0.5 mg, Minizide 5, Pfizer.

Capsules, 1, 2, and 5 mg /Prazosin HCl/

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine.

2-(4-(2-FUROYL)PIPERAZIN-1-YL)-4-AMINO-6,7-DIMETHOXYQUINAZOLINE

Applications · 3 items

UsesPrazosin Hydrochloride (Terazosin EP Impurity K) is an antihypertensive. α1-Adrenergic blocker.

UsesPrazosin hydrochloride has been used:to block the α1adrenergic receptors that mediate sympathetic vasoconstriction in miceas an α1-adrenoceptor blocker,administered intragastrically in ratsas a vasodilator,administered together with inuslin into the left ventricle of mice for the assessment of its effects on renal functions

General DescriptionThe antihypertensive effectsof prazosin hydrochloride, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride(Minipress), are caused by peripheral vasodilation as a resultof its blockade of 1-adrenergic receptors. In ligand-bindingstudies, prazosin hydrochloride has 5,000-fold greater affinityfor α1-receptors than for some α2-adrenergic receptors.

Upstream & downstream products

Upstream raw materials

2,4-Dichloro-6,7-dihydro-5H-cyclopentapyrimidine2-Furoyl chlorideAmmonia2-Chloro-4-amino-6,7-dimethoxyquinazolinePiperazine

Suppliers100 total

国药集团化学试剂有限公司86-21-63210123 · [email protected]
北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
济南百隆化学有限公司[email protected] · [email protected]
广州隽沐生物科技股份有限公司020-36607679; 13502246435 · [email protected]
湖北金梭生物科技有限公司00123456789 · [email protected]
河北展药生物科技有限公司15369953316 +8615369953316 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
重庆康洲智通医药科技有限公司173-08362167 17308362167 · [email protected]
Dayang Chem (Hangzhou) Co.,Ltd.+86-0571-88938639 17705817739 · [email protected]
南京世洲生物科技有限公司025-025-85560043 17301488900 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
上海迈瑞尔生化科技有限公司4006356688 18621169109 · [email protected]
深圳市简一生物科技有限公司0755-84826604 · [email protected]
武汉易泰科技有限公司上海分公司18930552037 · [email protected]
安耐吉化学&3A(安徽泽升科技股份有限公司)400-0056266 · [email protected]
常州科化生物科技有限公司0519-68985668 13685222090 · [email protected]
广州市亿邦医药科技有限公司+86 (20) 28996708,29078958,28139708,29076128,28133708,28139728,28139738,28133718,021-31663278,021-31663578,021-60538387
北京绿百草科技发展有限公司010-61136123 · [email protected]
上海相辉医药科技有限公司13761987713 · [email protected]
Ascent Scientific4401179829988 · [email protected]
上海泰坦科技股份有限公司4006009262 13023226327 · [email protected]
BOC Sciences1-631-485-4226; 16314854226 · [email protected]
孝感深远化工有限公司15527621225; 15527621225 · [email protected]
斯百全化学(上海)有限公司021-021-021-67601398-809-809-809 15221380277 · [email protected]
AdooQ BioScience, LLC+1 (866) 930-6790 · [email protected]
TCI AMERICA800-4238616 · [email protected]
TOKYO CHEMICAL INDUSTRY CO., LTD.03-36680489 · [email protected]
TCI Europe320-37350700 · [email protected]
广州爱纯医药科技有限公司020-39119399 18927568969 · [email protected]
南京生利德生物科技有限公司025-57798810 18652991625 · [email protected]
HBCChem, Inc.+1-510-219-6317 · [email protected]
湖南华腾制药有限公司400-8592883 15367835770 · [email protected]
上海御略医药科技有限公司021-60345187 13671753212 · [email protected]
杭州杰恒化工有限公司0571-87396432 · [email protected]
南京百鑫德诺生物科技有限公司025-58849295 · [email protected]
广州市慈铭生物科技有限公司020-38082199,29065168,38082986,29878298,29866629,4000192398
上海孚一生物科技有限公司+86 (21) 61124340
凯试(上海)科技有限公司021-50135380 · [email protected]
Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336 · [email protected]
天津阿尔塔科技有限公司022-6537-8550 15522853686 · [email protected]
TargetMol中国(陶术生物)021-021-33632979 15002134094 · [email protected]
Alfa Chemistry1-516-6625404 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
九鼎化学(上海)科技有限公司4009209199 · [email protected]
Standardpharm Co. Ltd.86-714-3992388 · [email protected]
sgtlifesciences pvt ltd+91-8790379245 · [email protected]
上海珞珐生化科技有限公司021-51111890 15317326293 · [email protected]
陕西缔都医药化工有限公司+86-29-81139210 +86-17392587031 · [email protected]
上海岚克医药科技发展有限公司0086-21-58956006